Mod­er­na eyes PhI­II start for com­bo mR­NA jab tar­get­ing Covid and flu af­ter PhI/II suc­cess

Mod­er­na’s com­bi­na­tion vac­cine can­di­date for Covid-19 and in­fluen­za, mR­NA-1083, has shown ear­ly po­ten­tial in a mid-stage tri­al, spark­ing plans for reg­is­tra­tional de­vel­op­ment lat­er this year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.